Growing East Bay biotech Scribe Therapeutics lines up potential $1.5 billion CRISPR deal
San Francisco Business Times
|
May 16, 2023
X min read
San Francisco Business Times
|
May 16, 2023
Share on Social
More like this
News
Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference
March 7, 2025
Read Now
Press
Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference
March 7, 2025
Read Now
